로딩 중…
지수 로딩 중…
HLB PANAGENE Co., LTD.
046210· KOSDAQ· Health Care· Pharmaceuticals, Biotechnology & Life Sciences
₩1,104+4.94%
2026-08-04
Financials
Valuation Metrics
HLB PANAGENE Co., LTD.'s Market Cap is ₩503B. At end of 2025 it was ₩790B. Ranked #1742 of 2,436 in KR market (top 72%), #1053 of 1,649 on KOSDAQ (top 64%), #191 of 234 in Pharmaceuticals, Biotechnology & Life Sciences (top 82%) by Market Cap.
Investment Metrics(as of 2026-08-04)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 50.26B KRW | KR#1,742/2,436 Sec#191/234 |
| Revenue | 14.64B KRW | KR#2,213/2,436 Sec#165/234 |
| Net Income | -3.62B KRW | KR—/2,436 Sec—/234 |
| Total Assets | 83.19B KRW | KR#1,883/2,436 Sec#156/234 |
| Net Assets | 74.62B KRW | KR#1,600/2,436 Sec#134/234 |
| Employees | 81 | KR#1,786/2,436 Sec#147/234 |
| Value | ||
| P/B | 0.67x | KR#1,112/2,436 Sec#58/234 |
| P/S | 3.43x | KR#2,045/2,436 Sec#132/234 |
| FCF Yield | -4.97% | KR—/2,436 Sec—/234 |
| Profitability | ||
| ROE | -4.85% | KR#1,741/2,436 Sec#129/234 |
| ROA | -4.35% | KR#1,857/2,436 Sec#139/234 |
| Op. Margin | -23.61% | KR#2,154/2,436 Sec#147/234 |
| Revenue Growth | -11.57% | KR#1,917/2,436 Sec#176/234 |
| Earnings Growth | -356.42% | KR#1,592/2,436 Sec#106/234 |
| Financial Health | ||
| Debt Ratio | 111.48% | KR#473/2,436 Sec#64/234 |
| Total Debt | 6.25B KRW | KR#1,739/2,436 Sec#164/234 |
| FCF | -2.50B KRW | KR#1,370/2,436 Sec#105/234 |
| Cash | 24.45B KRW | KR#1,121/2,436 Sec#79/234 |
| Current Ratio | 4.79x | KR#311/2,436 Sec#60/234 |
| Performance | ||
| 1Y Return | -42.83% | KR#1,911/2,436 Sec#170/234 |
| 1M Return | -24.59% | KR#2,300/2,436 Sec#227/234 |
| From 52W High | -62.45% | KR#1,835/2,436 Sec#154/234 |
| 1Y MDD | -62.30% | KR#1,540/2,436 Sec#123/234 |
| Trading | ||
| Volume | 185,057 shares | KR#607/2,436 Sec#58/234 |
| Foreign Own. | 1.98% | KR—/2,436 Sec—/234 |
| Per Share | ||
| EPS | -80 KRW | KR—/2,436 Sec—/234 |
| BPS | 1,639 KRW | KR#2,124/2,436 Sec#182/234 |
Company Info
동사는 2001년 설립, 2008년 코스닥 상장, 2023년 상호를 에이치엘비파나진으로 변경함. 주력 사업은 인공 유전자인 PNA를 활용한 소재 및 분자진단 사업을 포함하며, (주)바이오스퀘어는 퀀텀팩 기술로 플랫폼 사업 확장 중임. AI 기반 진단 플랫폼 구축, PNA 신약개발로 예방, 진단, 치료를 아우르고 의료 밸류체인 확보하여 정밀진단 종합 솔루션 확대 추진하고 있음. HLB파나진는 1976년에 설립되었으며 대전광역시 유성구에 본사를 두고 있습니다.